<DOC>
	<DOCNO>NCT02454764</DOCNO>
	<brief_summary>After fulfillment selection criterion , patient include trial administer Tenofovir continue 3 month stop 1 month , LFT 's , HBV DNA , HBsAg , check weekly time period stop Tenofovir thereafter 4 month patient ALT &gt; /= 1.5 time ULN randomise 2 group administer either Peg INF alpha 2b + Tenofovir ( dose ) Tenofovir alone continue 48 week patient rise ALT exclude . Patients closely monitored period stop tenofovir post pulse therapy liver function test perform weekly . Patients closely observe development acute hepatitis decompensation 4 - week period drug withdrawal . Thereafter , CBC , KFT , LFT 's , PT-INR , HBsAg ( Q ) , HBeAg HBV DNA level test every 3 month . After stop treatment followup do 24 week post stoppage treatment look sustain seroconversion virological/biochemical response</brief_summary>
	<brief_title>'Tenofovir Pulse Peg Interferon Alpha 2b ' Therapy HBeAg-positive Patients With Normal ALT</brief_title>
	<detailed_description />
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>1 . Treatment naive chronic HBV infection i.e detectable HBsAg past 6 month , 2 . HBeAg ( + ) , 3 . ALT &lt; ULN ( Upper Limit Normal ) 2 occasion last 6 month [ ULN : 45 ] 4 . HBV DNA &gt; 2000 IU/mL 5 . Age &gt; 18 year 1 . Decompensated Cirrhosis 2 . Severe HBV flare reactivation 3 . Presentation ACLF ( Acute Chronic liver Failure ) 4 . Baseline ALT &gt; ULN ( Upper Limit Normal ) 5 . Contraindications PEGIFN therapy 6 . Prior HBV antiviral therapy within 6 month enrollment 7 . Coinfections HCV/HIV 8 . ANA + ( autoantibody suggestive autoimmune disease ) &gt; 1:80 9 . Patient willing enrollment study 10 . Pregnancy , lactation 11 . Patients leave study/ discontinue therapy completion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>